Review Article
Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban
Table 4
Relative risk reductions (RRRs) of efficacy outcome event rates versus VKA control groups.
| | RE-LY [21] | ROCKET AF [14] | ARISTOTLE [15] | | Dabigatran 110 mg BD | Dabigatran 150 mg BD | Rivaroxaban | Apixaban |
| Primary outcome RRR, % | 10* | 35* | 21* | 21* | Haemorrhagic stroke RRR, % | 69* | 74* | 41* | 49* | Ischaemic/unknown stroke RRR, % | 11 | 24* | 6 | 8 | CV death RRR, % | 10 | 15* | 11 | 11 | All death RRR, % | 9 | 12 | 15 | 11* | MI RRR, % | 29 | 27 | 19 | 12 |
|
|
BD: twice daily; RRR: relative risk reduction.
*
P < 0.05.
|